Colorectal cancer screening data: behavioral signals and the colonoscopy avoidance window
Roughly 30% of adults eligible for colorectal cancer screening have never been screened, and behavioral data shows a predictable avoidance window between first recommendation and first procedure. Colorectal cancer screening data reveals patterns that clinical systems miss: search spikes, appointment cancellations, and months of delay that map to preventable late-stage diagnoses.
About 60 million Americans are overdue for colorectal cancer screening. The clinical infrastructure exists. The guidelines are clear. The screening modalities are accessible. Yet colorectal cancer remains the second leading cause of cancer death in the United States, killing roughly 53,000 people per year. The problem is not clinical. It is behavioral.
Colorectal cancer screening data tells a story that EHR records alone cannot. Between the moment a provider recommends a colonoscopy and the moment a patient schedules one, there is a measurable gap. We call it the colonoscopy avoidance window. And it is where preventable deaths accumulate.
The avoidance window is measurable
The American Cancer Society estimates that only 59% of eligible adults are up to date on CRC screening. Among those who eventually complete screening, the median delay between recommendation and scheduling is 7 to 12 months, according to studies published in Gastroenterology. For a significant subset, that delay extends past 18 months or becomes permanent avoidance.
Behavioral signals during this window are visible in search data, appointment system records, and patient portal activity. Patients search for alternatives to colonoscopy. They read about Cologuard. They look up sedation risks, bowel prep instructions, and cost estimates. Then many of them stop engaging entirely.
This is not random. It follows a pattern, and that pattern is detectable if you have the right data layer.
What the 321 rule for colon cancer means
The 321 rule is a simplified screening guideline: get screened starting at age 3(x15, meaning 45), repeat every 2 intervals based on your chosen method, and follow up within 1 year if results are abnormal. In practice, the rule reminds patients that screening is not a one-time event. It requires adherence to a schedule. The 321 framework has gained traction as a patient education tool because it reduces the cognitive load of remembering complex guideline intervals.
But even with simplified rules, adherence breaks down. The behavioral data shows that patients who search "321 rule colon cancer" are often already behind schedule and looking for reassurance that they have not waited too long.
Seven early warning signs of colon cancer
The seven early warning signs most commonly cited in clinical literature are: persistent changes in bowel habits, rectal bleeding or blood in stool, persistent abdominal discomfort (cramps, gas, pain), a feeling that the bowel does not empty completely, weakness or fatigue, unexplained weight loss, and narrow or ribbon-like stools.
Search data shows that patients frequently search these symptoms individually, without connecting them to CRC risk. "Blood in stool causes" and "why am I so tired" are searched millions of times per month. The behavioral signal is not the individual search. It is the clustering of multiple symptom searches within a short window from the same population segments.
Why some doctors are skeptical of Cologuard
Cologuard, the at-home stool DNA test, has a sensitivity of 92% for colorectal cancer but only 42% for advanced adenomas. Its false positive rate runs between 13% and 15%. Many gastroenterologists express concern that a positive Cologuard result still requires a follow-up colonoscopy, creating a two-step process that adds delay and anxiety. Some physicians also worry that patients treat a negative Cologuard result as definitive when it misses nearly 60% of advanced precancerous lesions.
From a data perspective, the issue compounds. Cologuard results that do not lead to follow-up colonoscopies create incomplete screening records. These records degrade CRC early detection data quality across population health systems.
At what age do you no longer need a colonoscopy
The USPSTF recommends screening for colorectal cancer from age 45 to 75. For adults aged 76 to 85, the decision should be individualized based on overall health, prior screening history, and patient preference. After age 85, screening is generally not recommended.
However, behavioral data shows that patients over 75 frequently search "do I still need a colonoscopy" and "colonoscopy age limit." These searches spike after provider visits where the conversation about stopping screening was ambiguous or absent. The signal matters because it reveals a gap in shared decision-making that clinical records do not capture.
Key statistics
Colonoscopy behavioral signals map to real clinical risk
VIOLET tracks over 750 oncology-related search terms and maps behavioral patterns across cancer types. For colorectal cancer, the colonoscopy avoidance window produces a distinct signal cluster: searches for bowel prep alternatives, sedation-free colonoscopy, colonoscopy cost without insurance, and Cologuard accuracy. These searches peak 2 to 4 weeks after annual wellness visits and again in March (Colon Cancer Awareness Month).
When these behavioral signals are combined with screening gap data from clinical systems, they identify specific populations at highest risk of delayed detection. This is not survey data. It is observed behavior at scale.
The challenge is that behavioral data and clinical screening data rarely live in the same system. EHRs capture whether a colonoscopy was completed. They do not capture the 11 months of avoidance behavior that preceded it, or the permanent dropoff for patients who never schedule at all. Connecting these layers requires data trust infrastructure that scores records for recency, provenance, and concordance before any AI model attempts to identify at-risk cohorts.
The data trust layer that screening programs need
Population health teams building CRC screening outreach programs face a compounding data quality problem. Patient addresses change. Insurance coverage lapses. Prior screening records from outside systems arrive without provenance. Outreach lists built on stale data produce wasted mailers and missed patients.
The Data Trust Index scores every health record across 8 dimensions before it enters an AI pipeline. For screening programs, the three most critical dimensions are Recency (is this patient's contact information current), Concordance (do records from multiple sources agree on screening history), and Provenance (where did this record originate and has it been verified). Without these scores, outreach programs operate on data they cannot verify, targeting patients who may have already been screened or who moved out of the service area years ago.
VIOLET maps behavioral signals across 750+ oncology search terms before patients reach a clinic. If your team is working on cohort identification, trial recruitment, or oncology market intelligence for CRC screening populations, contact Louis Simeonidis at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
750+ cancer search terms. Live in production.
VIOLET maps behavioral signals 12–18 months before clinical presentation.